// App-Quantinova.ai

P649 : Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)

Researchers

Presenter

  • I Visuri

Principal Investigators

  • C Eriksson

  • E Mrdberg

  • O Grip

  • A Gustavsson

  • H Hjortswang

  • P Karling

  • S Montgomery

  • P Myrelid

  • O Oln

  • J F Ludvigsson

  • J Halfvarson

Medical Centers

  • Orebro University, Department of Gastroenterology, Faculty of Medicine and Health, Orebro, Sweden

  • Lund University, University Hospital MAS, Department of gastroenterology, Malmoe, Sweden

  • Central Hospital, Department of Internal Medicine, Karlstad, Sweden

  • Linkoping University, Dept. of Clinical and Experimental Medicine, Linkoping, Sweden

  • Linkoeping University, Gastroenterology, Linkoeping, Sweden

  • Umea University Hospital, Department of Public Health and Clinical Medicine, Umea, Sweden

  • Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro, Sweden

  • University College London, Department of Epidemiology and Public Health, London, UK

  • Karolinska Institutet, Cardiology Unit, Department of Medicine, Solna, Stockholm, Sweden

  • Linkoping University Hospital, Dept of Surgery, Linkoping, Sweden

  • Stockholm South General Hospital, Sachs’ Children and Youth Hospital, Stockholm, Sweden

  • Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden

  • Karolinska Institutet, Department of Medical Epidemology and Biostatistics, Stockholm, Sweden

  • Orebro University Hospital, Department of Cardiology, Örebro, Sweden

Locations

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved